Lobuglio A F, Saleh M, Peterson L, Wheeler R, Carrano R, Huster W, Khazaeli M B
Hybridoma. 1986 Jul;5 Suppl 1:S117-23.
Twenty patients with metastatic gastrointestinal cancer received one or more weekly infusions of 400 mg CO17-1A monoclonal antibody. The most common side effect was mild gastrointestinal symptoms in 9/20 patients. Two of five patients receiving three weekly infusions had reversible anaphylactic reactions at the time of their third infusion. The pharmacokinetics of the antibody were similar at the first, second or third infusion. Human antibody to 17-1A occurred in 17/20 patients with 11/20 having antibody detectable by 8 days following initial infusion. Thus, one or two infusions (weekly) of large doses of 17-1A were well tolerated but allergic responses limit ability to administer therapy by 15 days post-initial infusion.
20例转移性胃肠道癌患者接受了每周一次或多次400毫克CO17 - 1A单克隆抗体输注。最常见的副作用是9/20的患者出现轻度胃肠道症状。在接受三次每周输注的五名患者中，有两名在第三次输注时出现了可逆性过敏反应。在第一次、第二次或第三次输注时，抗体的药代动力学相似。20例患者中有17例产生了抗17 - 1A人抗体，其中11/20的患者在初次输注后8天可检测到抗体。因此，每周一次或两次大剂量输注17 - 1A耐受性良好，但过敏反应限制了在初次输注后15天内进行治疗的能力。
